-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 24, 2021, Kangfang Bio-Bio announced that the PD-1 antibody AK105 was selected for the FDA's real-time tumor review (RTOR) new policy, and it has initiated the BLA application for third-line nasopharyngeal carcinoma.
In addition to Hengrui Pharmaceuticals, the first echelon of domestic PD-1 has completed the blockbuster license-out transaction.
to sum up
In March 2021, Junshi Biologics submitted a rolling listing application for PD-1 antibody (nasopharyngeal cancer) to the FDA.